PTC Therapeutics wins Russian approval for Translarna for nmDMD
US-based PTC Therapeutics has secured marketing approval in Russia for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The approval for Translarna has been given by the Ministry of Health of the Russian Federation for Duchenne muscular dystrophy caused by a nonsense mutation in patients, aged two years and older. Stuart […]